Alberto Horenstein

List of Publications by Year
in descending order

36 papers	2,888 citations	257450 24 h-index	361022 35 g-index

36 all docs	36 docs citations	36 times ranked	3668 citing authors

#	Article	IF	Citations
1	Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology. Physiological Reviews, 2008, 88, 841-886.	28.8	727
2	Human CD38: a glycoprotein in search of a function. Trends in Immunology, 1994, 15, 95-97.	7.5	331
3	CD38 and CD157: A long journey from activation markers to multifunctional molecules. Cytometry Part B - Clinical Cytometry, 2013, 84B, 207-217.	1.5	236
4	A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. OncoImmunology, 2013, 2, e26246.	4.6	216
5	CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma. Frontiers in Immunology, 2018, 9, 2722.	4.8	124
6	CD56brightCD16â˜' NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation. Journal of Immunology, 2015, 195, 965-972.	0.8	111
7	NAD+-Metabolizing Ectoenzymes in Remodeling Tumorâ€"Host Interactions: The Human Myeloma Model. Cells, 2015, 4, 520-537.	4.1	99
8	c-kit Is Expressed in Soft Tissue Sarcoma of Neuroectodermic Origin and Its Ligand Prevents Apoptosis of Neoplastic Cells. Blood, 1998, 91, 2397-2405.	1.4	94
9	Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells. Journal of Immunology, 1996, 156, 727-34.	0.8	87
10	Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma. Molecular Medicine, 2016, 22, 694-704.	4.4	81
11	A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation. Oncotarget, 2015, 6, 25602-25618.	1.8	79
12	Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD⁺. OncoImmunology, 2018, 7, e1458809.	4.6	59
13	CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy. Frontiers in Immunology, 2019, 10, 760.	4.8	56
14	Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche. Frontiers in Immunology, 2017, 8, 305.	4.8	52
15	Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation. Oncotarget, 2017, 8, 56598-56611.	1.8	52
16	Canonical and non-canonical adenosinergic pathways. Immunology Letters, 2019, 205, 25-30.	2.5	48
17	Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Annals of the New York Academy of Sciences, 2015, 1335, 10-22.	3.8	47
18	CD38 and CD157 Ectoenzymes Mark Cell Subsets in the Human Corneal Limbus. Molecular Medicine, 2009, 15, 76-84.	4.4	46

#	Article	IF	Citations
19	The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases. Mediators of Inflammation, 2018, 2018, 1-10.	3.0	38
20	CD38 binding to human myeloid cells is mediated by mouse and human CD31. Biochemical Journal, 1998, 330, 1129-1135.	3.7	36
21	CD38 in the age of COVID-19: a medical perspective. Physiological Reviews, 2021, 101, 1457-1486.	28.8	32
22	Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells. OncoImmunology, 2019, 8, e1574198.	4.6	29
23	The ADP-ribosyl cyclases - the current evolutionary state of the ARCs. Frontiers in Bioscience - Landmark, 2014, 19, 986.	3.0	28
24	<scp>CD</scp>38 modulates respiratory syncytial virusâ€driven proinflammatory processes in human monocyteâ€derived dendritic cells. Immunology, 2018, 154, 122-131.	4.4	28
25	CD38 and bone marrow microenvironment. Frontiers in Bioscience - Landmark, 2014, 19, 152.	3.0	26
26	The Circular Life of Human CD38: From Basic Science to Clinics and Back. Molecules, 2020, 25, 4844.	3.8	17
27	Molecular dynamics of targeting CD38 in multiple myeloma. British Journal of Haematology, 2021, 193, 581-591.	2.5	16
28	Antibody mimicry, receptors and clinical applications. Human Antibodies, 2017, 25, 75-85.	1.5	15
29	Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors. Frontiers in Pharmacology, 2018, 9, 196.	3.5	15
30	Unconventional, adenosine-producing suppressor T cells induced by dendritic cells exposed to BPZE1 pertussis vaccine. Journal of Leukocyte Biology, 2015, 98, 631-639.	3.3	14
31	Ectonucleotidase Expression on Human Amnion Epithelial Cells: Adenosinergic Pathways and Dichotomic Effects on Immune Effector Cell Populations. Journal of Immunology, 2019, 202, 724-735.	0.8	13
32	Functional insights into nucleotide-metabolizing ectoenzymes expressed by bone marrow-resident cells in patients with multiple myeloma. Immunology Letters, 2019, 205, 40-50.	2.5	11
33	CD73/Adenosine Pathway Involvement in the Interaction of Non-Small Cell Lung Cancer Stem Cells and Bone Cells in the Pre-Metastatic Niche. International Journal of Molecular Sciences, 2022, 23, 5126.	4.1	9
34	CD38 and Antibody Therapy: What Can Basic Science Add?. Blood, 2016, 128, SCI-36-SCI-36.	1.4	8
35	c-kit Is Expressed in Soft Tissue Sarcoma of Neuroectodermic Origin and Its Ligand Prevents Apoptosis of Neoplastic Cells. Blood, 1998, 91, 2397-2405.	1.4	8
36	CD38 Induces Homing of Chronic Lymphocytic Leukemia Cells to the Lymphoid Organs through a Functional Interplay with CXCR4.. Blood, 2009, 114, 2328-2328.	1.4	0